RxDoctor Payments Data

Mir Alikhan, MD

Internal Medicine · Lake Worth, FLNPI 1821054008

Payments from drug & device makers

$1,142in general payments, 2019–2025

Across 43 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$498
  • Bayer$125
  • Pfizer$116
  • Johnson & Johnson$86
  • Lilly USA, LLC$73
  • Sumitomo Pharma America, Inc.$38
  • plus $206 from 9 others

What the payments were for

  • Food & beverage$83173%
  • Education$31127%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,142 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$35,187
Medicare patients
107
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$190,347
EliquisApixaban168$171,431
OzempicSemaglutide63$74,204
MyrbetriqMirabegron49$46,185
ProliaDenosumab24$42,020
EntrestoSacubitril/Valsartan27$39,631
FarxigaDapagliflozin Propanediol24$36,897
MounjaroTirzepatide31$34,802
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$29,697
XareltoRivaroxaban19$25,766
Saxagliptin Hcl22$22,060
BrilintaTicagrelor11$12,503
VascepaIcosapent Ethyl13$12,481
LinzessLinaclotide14$12,346
TrulicityDulaglutide12$11,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$190,347151 claims
PfizerEliquis$116$171,431168 claims
Novo NordiskOzempic$24$74,20463 claims
AstraZenecaFarxiga, Brilinta$16$49,40035 claims
Astellas Pharma US IncMyrbetriq$498$46,18549 claims
Lilly USA, LLCMounjaro, Trulicity$73$46,05143 claims
NovartisEntresto$38$39,63127 claims
GSKTrelegy Ellipta, Anoro Ellipta$21$39,04236 claims
Johnson & JohnsonXarelto$86$25,76619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lake Worth

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →